Designing Longevity
Skip to main content

Compare Gut Health & Digestion Options

Start with the symptom or diagnosis that brought you here. Compare prescription and over-the-counter options for specific constipation conditions, find out where specialist peptide treatment fits, or check the evidence behind a gut health claim.

Sources reviewed November 13, 2026 · How we work

Our picks for specific needs

Flexible mealtime timing for adult IBS with constipation

Trulance 3 mg tablets

U.S. 30-tablet bottle · NDC 65649-003-30

FDA-approved prescription medicine

The Trulance label allows taking it with or without food. The Linzess label calls for an empty stomach at least 30 minutes before a meal.

This pick compares mealtime instructions. The American Gastroenterological Association gives Linzess stronger guideline support for IBS with constipation. Discuss symptoms, side effects and coverage with your clinician.

Compare IBS-C medicines

Sources checked (U.S. Eastern time)

Focused comparisons

What would you like help with?

Products and peptide evidence

FDA-approved peptide medicine

Linzess (linaclotide) capsules

Labeled for IBS with constipation in adults and ages 7 and older, chronic idiopathic constipation in adults, and functional constipation in children ages 2 and older. The adult comparisons use the presentations studied for each diagnosis.

FDA-approved specialist peptide medicine

Gattex (teduglutide) 5 mg vial

Labeled for people ages 1 and older with short bowel syndrome who depend on nutrition or fluids delivered into a vein. Studies measured reductions in the amount of that support.

Research-only · No FDA approval for digestive care

KPV

Cell and mouse colitis studies measured inflammation. FDA’s review found no human exposure data for drug products containing KPV.

Open research notice

For research use only

Products sold for laboratory research aren’t intended for use in people. Continuing opens the FDA evidence review.

Continue for research

For research use only

Products sold for laboratory research aren’t intended for use in people. Continuing opens the FDA evidence review.

Continue for research
Research-only · No FDA approval for digestive care

BPC-157

Animal studies have explored injury and repair. Evidence that BPC-157 improves human digestive symptoms or treats inflammatory bowel disease is unestablished.

Open research notice

For research use only

Products sold for laboratory research aren’t intended for use in people. Continuing opens the FDA evidence review.

Continue for research

For research use only

Products sold for laboratory research aren’t intended for use in people. Continuing opens the FDA evidence review.

Continue for research